Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 443 (TSXV: $IGX.V) (OTCQB: $IGXT) (CSE: $BEV.C)(OTCQB: $WRHLF)
Delta, Kelowna, BC, July 20, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site,www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) today announced that it and Tilray, Inc. have amended the exclusivity terms of their November 2018 license, development and supply agreement to allow for IntelGenx’s co-development and commercialization of CBD products with additional partners. In consideration, IntelGenx shall pay a royalty to Tilray on all CBD products sold pursuant to this amendment. All other terms of the Agreement, including those pertaining to Tilray’s exclusive, worldwide marketing and distribution rights for non-CBD cannabis-infused VersaFilm®, remain unchanged.
“Since obtaining our cannabis micro-processing license from Health Canada a few weeks ago, we have received numerous expressions of interest from cannabis industry players in our drug delivery platforms and manufacturing capabilities, as we continue to have the only Health Canada licensed and GMP compliant facility for pharmaceutical film manufacturing,” commented Dr. Horst G. Zerbe, CEO of IntelGenx. “While we continue to work with Tilray® to align on the timing of a potential commercial launch of our first co-developed cannabis-infused VersaFilm® product, we are now actively seeking other potential partners to commercialize CBD-containing film products targeting the health and wellness market in Canada.”
Ikänik Farms, Inc. announced that Pideka SAS, a wholly owned Colombian subsidiary of the Company, has signed a collaborative agreement with CAS Biotechnology, for cannabis research on the potential medical benefits in the treatment of COVID-19, with pharmaceutical grade cannabis oil provided by the company's GACP and GMP-Pharma certified Casa Flores facility, located outside of Bogota, Colombia. The company's cannabis is supported by agronomically certified genetics and is currently sold in Colombia for use in Formula Magistral.
"We are excited to partner with CAS Biotechnology on the first export of pharmaceutical grade Cannabis to Mexico, in hopes to aid in the treatment of COVID-19," said Borja Sanz de Madrid, President of Ikänik International.
The testing will be conducted by CAS Biotechnology's scientific team at their research facility in Mexico. CAS Biotechnology's team is comprised of scientists with expertise in molecular and synthetic biology, bioinformatics, genomics, proteomics, and pre-clinical trials. Pideka will provide samples to CAS Biotechnology for conducting scientific research and pre-clinical trials to determine the effect of Cannabis oil on SARS-CoV-2's replication cycle.
"We are very proud to participate in a study that brings medicine and cannabis closer together, in a joint effort to discover possible Phyto therapeutic treatments, as a new course of action for the treatment of COVID-19," said Brian Baca, CEO of Ikänik Farms.
BevCanna Enterprises Inc. (CSE: BEV) (OTC: BVNNF) announced today that it has entered into a non-binding letter of intent to manufacture white-label CBD and THC-infused beverages for rising British Columbian beverage brand State B Beverage Co. Launched by well-known B.C. mixologist and Master Drink Maker Kelly Ann Woods, State B is part of the Brujera Elixirs Incorporated house of brands which currently includes Boozewitch (sober-curious mixers) and three additional functional human performance drinks in development.
Under the proposed agreement, BevCanna will leverage its extensive experience developing and launching beverages in the Canadian market to create the new State B beverage concept, which will be a merge of functional beverages and cannabis drinks. BevCanna will also maintain responsibility for regulatory compliance with Health Canada.
State B will hold responsibility for national sales and marketing efforts to launch the product line in Canada. The white label agreement will be for an initial term of three years with a subsequent three-year renewal option.
"The State B brand is an intriguing new concept, and we're excited to be the ones to launch the new line," said John Campbell, Chief Strategic Officer at BevCanna. "Our plan to create a sustainable consistent revenue stream through our white-label portfolio is well on track, and adding the State B brand will add to the momentum."
"BevCanna's experience in formulating functional yet very appealing beverages was exactly what we were looking for in a white-label partner," said Kelly Ann Woods, CEO of Brujera. "Their success in bringing great concepts to life, while maintaining strict regulatory compliance, convinced us that they were the right partner to work with on our new brand."
World High Life (OTCQB: WRHLF) announced having seen considerable sales numbers lead to two substantial quarters of growth from its wholly owned subsidiary, Love Hemp. Tony Calamita, the Chief Executive Officer (CEO) of Love Hemp, a London-based CBD company spearheading the development of the United Kingdom’s (UK) leading range of trusted CBD products, has the company hitting on all cylinders as it heads into the second half of the year.
Although the global COVID-19 crisis has many businesses treading water and searching for answers, Love Hemp hasn’t missed a beat while meeting these trying times head on, the company has thrived by giving customers exactly what they want—plenty of online options and continued product development.
Love Hemp has over 80 products, including oils, sprays, edibles, cosmetics, and vapes, and the company currently enjoys around 1,200 retail listings, but World High Life’s subsidiary has no plans of stopping there. Love Hemp prides itself on understanding market demand and developing new products and brands that satisfy what consumers want most. Calamita says that new product development is at the heart of everything the company does. “We currently have 15 new products in the development stage, and we remain committed to creating the UK’s leading range of trusted CBD products.”
Last week, one of those newly developed brands was launched into the market. World High Life announced Love Hemp’s new brand, Buzz Leaf, a host of products aimed at younger consumers that include the release of four broad-spectrum CBD infused e-liquids with added terpenes, and eventually the launch of a full range of CBD products, including CBD oils and capsules. According to the company, the e-liquids feature exotic flavors that contain 500mg of CBD.
Given the exponential growth that the company’s e-commerce business has seen and the sheer number of customers, who are not only finding Love Hemp online but continuing to come back again and again, Love Hemp has redesigned its global online retailer, https://www.CBDOilsUK.com, a premium CBD oil and cannabidiol supplier in the UK, to handle the overwhelming demand. Calamita says that with the launch of the Buzz Leaf products, there is now something for everyone on the website.
Tony Calamita, discussing the successful results that Love Hemp has enjoyed in Q1 and Q2 said, “The COVID-19 pandemic affected consumer markets and is accelerating existing trends within the consumer sector. When the pandemic began, we saw a shift in retail, which resulted in the acceleration of the e-commerce market as consumer demand shifted to shopping online.
“As a result, we achieved a 107% increase in online sales from January to May 2020. This was an incredibly strong period of sales for Love Hemp, and while our strong growth usually comes from a wider variety of sales channels, given the challenging business circumstances, our shift to the expansion of our online products has enabled us to ensure our customers are able to continue to purchase and to engage with us. We are focused on building trust and credibility with our consumer base and to continue to innovate while responding to evolving consumer demands.”
Sales of the company’s CBD oil, CBD oil sprays, and CBD soft gel capsules are leading the way, but the timely introduction of another new product, Love Hemp Immune, well ahead of schedule, is already growing in popularity among customers. Love Hemp Immune is advertised as a blend of CBD, essential vitamins, including vitamins C and D, and bilberry extract to maintain a healthy immune system by supporting our body’s natural defenses.
Calamita added, “We’ve also seen a greater interest in health and wellness as COVID-19 reinforced the importance of being healthy and maintaining a strong, balanced immune system.
“Since its launch, Love Hemp Immune has been well received by consumers. It was a product that was due to launch in the Winter of 2020, but, instead, we worked around the clock to ensure that consumers could have access to it much sooner as COVID-19 and a nationwide lockdown hit the UK, a time when boosting our immune systems has rarely felt more urgent. It contains the perfect combination of beneficial ingredients to help boost the body’s natural defenses. The importance of being flexible and agile while responding to consumer needs has never been more crucial.”
So, where does World High Life’s subsidiary go in the second half of the year? The announcement of the Buzz Leaf brand is certainly a good start and defines what is likely Love Hemp’s plan to get those 15 products/brands that are in development to market. Love Hemp’s CEO says, “As retail stores begin to reopen, we’re focused on holistic growth across all channels from retail to online. We are in conversations with all major retailers in the UK, and we look forward to continued growth among our customer base, while maintaining brand loyalty among consumers.”
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at Investorideas.com potcasts - cannabis news and stocks to watch plus insight from thought leaders and experts
To hear more Investorideas.com podcasts visit:Investorideas.com Investing and trading ideas Podcasts about bitcoin, blockchain, biotech, cannabis, cleantech, sports, mining, tech, support and resistance trading, now on iTunes, Spotify, Google Play Music, iHeart.com, Spreaker, SoundCloud.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles,podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns :Crypto Corner ,Play by Play sports and stock news column,Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change ,Exploring Mining theAI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: InvestorIdeas - Disclaimer, full disclosure, compensation disclosure Learn more about publishing your news release and our other news services on the Investorideas.com newswire Investorideas.com Stock News, Newswire, press release, social media and ticker tag articles services for TSX stocks, CSE.com stocks, NYSE stocks, NASDAQ stocks, OTC stocks and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitterhttps://twitter.com/Investorideas
Follow us on FacebookInvestorideas.com -Investing Ideas
Follow us on YouTubeInvestorIdeas.com - news that inspires big ideas
Download ourMobile App for iPhone and Android
Join our Investor ClubJoin Investorideas.com and get investing podcasts and ideas for cannabis, cleantech and climate change, artificial intelligence, crypto and blockchain, vegan, mining, and esports stocks
800 665 0411
Analyst's Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.